Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05658497

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks after the first day of their last menstrual period (LMP) up through the first trimester of pregnancy and to comparatively evaluate pregnancy outcomes with MCMs in women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the first trimester of pregnancy with the following: i) women with MS who were unexposed to disease modifying therapies (DMTs) and, ii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries).

The secondary objective of the study is to evaluate pregnancy outcomes in women with DRF exposure at any time from 2 weeks after the first day of their LMP through the end of pregnancy compared with the following: i) women with MS who were unexposed to DMTs, ii) women with dimethyl fumarate (DMF) exposure, iii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries), and iv) women without MS (e.g., women from external, general population comparators).

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

Female

Study type

Observational

Primary location

Austin Hospital, Heidelberg, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Participant must have a diagnosis of MS
  • Documentation that the participant was one of the following:
  • exposed to DRF at any time from 2 weeks after the first day of their LMP (i.e., conception date) up through any time during pregnancy. (If exact exposure dates are unknown, the reporter must be able to specify or estimate trimester of exposure).
  • unexposed to any DMT during pregnancy, defined as having never received DMT therapy; discontinued treatment with DRF at least 1 day before 2 weeks after the first day of their LMP (i.e., conception date); or discontinued a non Registry-specified MS DMT more than 5 times its half-life prior to 2 weeks after the first day of their LMP (i.e., conception date)
  • Participants with knowledge of the outcome of the pregnancy (e.g., pregnancy loss or live birth)

Key Exclusion Criteria:

  • None

NOTE: Other protocol defined Inclusion criteria may apply

Treatment and study plan

Diroximel Fumarate

Drug

Administered as specified in the treatment arm.

Other names: VUMERITY, BIIB098

Avonex

Drug

Administered as specified in the treatment arm.

Other names: BG9418, interferon beta-1a

Tysabri

Biological

Administered as specified in the treatment arm.

Other names: Natalizumab, BG00002

dimethyl fumarate

Drug

Administered as specified in the treatment arm.

Other names: Tecfidera, DMF, BG00012

Primary outcomes

  1. Number of Major Congenital Malformations (MCMs)

    Time frame: Up to 52 weeks postdelivery

    MCMs include abnormalities in structural development that are medically or cosmetically significant are present at birth, and persist in postnatal life unless or until repaired as evaluated by independent advisors used throughout the registry.

Secondary outcomes

  1. Number of Elective or Therapeutic Terminations

    Time frame: Up to 9 months of pregnancy

    Elective or therapeutic pregnancy termination is any induced or voluntary fetal loss during pregnancy. It will be subclassified as elective or therapeutic pregnancy terminations as whether it was due to a fatal anomaly or not.

  2. Number of Spontaneous Abortions

    Time frame: Before 22 weeks of gestation

    Spontaneous abortion is defined as any loss of a fetus due to natural causes before 22 weeks of gestation.

  3. Number of Fetal Deaths Including Still Birth

    Time frame: At or after 22 weeks of gestation

    Fetal death or stillbirth refers to the death of a fetus prior to complete expulsion or extraction from its mother at or after 22 weeks of gestation. Death is indicated by the fact that, after such separation, the fetus does not show any evidence of life (e.g., heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles). Fetal death occurring at or after 22 weeks but before 28 weeks of gestation is considered an early fetal loss. Fetal death occurring at or after 28 weeks is considered a late fetal loss.

  4. Number of Live Births

    Time frame: Up to delivery (approximately 10 months)

    A live birth refers to a complete expulsion or extraction from its mother of a surviving neonate breathing, or showing any other evidence of life, such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles, whether the umbilical cord has been cut or the placenta is attached. Any live birth before 37 weeks of gestation will be considered premature birth. Any live birth at or after 37 weeks but before 42 weeks of gestation will be considered full-term birth. Any live birth at or after 42 weeks of gestation will be considered post-term birth.

  5. Number of Ectopic Pregnancies

    Time frame: Up to 9 months of pregnancy

  6. Number of Molar Pregnancies

    Time frame: Up to 9 months of pregnancy

  7. Number of Maternal Deaths

    Time frame: Up to 12 weeks postdelivery

    Maternal death is death of a pregnant woman during pregnancy, labor, or delivery. Registry will also report maternal deaths that occur up to 12 weeks postdelivery.

  8. Number of Neonatal Deaths

    Time frame: Prior to 28 days postdelivery

    Neonatal death is death occurring in a neonate prior to 28 days of life.

  9. Number of Perinatal Deaths

    Time frame: At or after 28 days to 12 weeks postdelivery

    Perinatal death is death occurring at or after 28 days of life and prior to 12 weeks of life.

  10. Number of Infant Deaths

    Time frame: Between 12 to 52 weeks postdelivery

    Infant death is death occurring between 12 and 52 weeks of life, inclusive.

  11. Number of Serious or Opportunistic Infections in Liveborn Children

    Time frame: Up to 52 weeks postdelivery

  12. Number of Infants with Abnormal Postnatal Growth and Development

    Time frame: Up to 52 weeks postdelivery

    Infant growth measurements will be used to estimate gender-specific weight-for-length, head circumference-for-age, length-for-age, and weight-for-age percentiles. Developmental milestones (i.e., social/emotional, language/communication, neurocognitive, movement/physical development) will be used to determine results of infant status (i.e., below, above, or at age-appropriate achievement).

  13. Number of Participants with Pregnancy Complications

    Time frame: Up to 9 months of pregnancy

    Pregnancy complications may include incidences of pre-eclampsia, eclampsia, pregnancy-induced hypertension, preterm labor, gestational diabetes and placenta previa.

Study contacts

Contact information is provided by the study sponsor or research team.

Global Biogen Clinical Trial Center

CONTACT

[email protected]

US Biogen Clinical Trial Center

CONTACT

[email protected]

866-633-4636

Sponsors and collaborators

Lead sponsor

Biogen

Industry

Registry information

Official study title

Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry

Important dates

Study start
2023
Primary completion
2032
Study completion
2032
First posted
Dec 20, 2022
Registry last updated
Aug 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.